Loading
A phase 3 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by RenovoRx, now recruiting.
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC is a phase 3 interventional study registered as NCT03257033 by RenovoRx, with 190 participants planned, started 2018-03-12 and due to reach its primary completion in 2027-06. Interventions recorded: Gemcitabine, nab-paclitaxel and RenovoCath.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.